Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by aliasunknownon Jun 12, 2018 6:55pm

136 Views

Post# 28162514

RE:Where's the bashers???

Not sure if this has been posted. Warrants exercised...............

Jun 10/18	Jun 7/18	Buret, Andre Gerald	Direct Ownership	Common Shares	54 - Exercise of warrants	50,000	$0.150
Jun 10/18	Jun 7/18	Buret, Andre Gerald	Direct Ownership	Warrants	54 - Exercise of warrants	-50,000	$0.150
Jun 10/18	Jun 5/18	Wu, Yung Cheng	Direct Ownership	Common Shares	54 - Exercise of warrants	500,000	$0.150
Jun 10/18	Jun 5/18	Wu, Yung Cheng	Direct Ownership	Warrants	54 - Exercise of warrants	-500,000	$0.150